EverPoint Asset Management’s Acorda Therapeutics ACOR Stock Holding History

EverPoint Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-208	Closed	-$522K	–	559
2016 Q3	$522K	Buy	+208	New	+$621K	0.01%	393
2016 Q2	–	Sell	-1,042	Closed	-$3.31M	–	536
2016 Q1	$3.31M	Hold	1,042	–	–	0.07%	280
2015 Q4	$5.35M	Sell	1,042 -208	-17%	-$909K	0.11%	238
2015 Q3	$3.98M	Buy	+1,250	New	+$4.85M	0.1%	248
2014 Q3	–	Sell	-2,500	Closed	-$10.1M	–	579
2014 Q2	$10.1M	Buy	+2,500	New	+$10.2M	0.21%	143

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

EverPoint Asset Management's ACOR Position: Q4 2016 in Review

EverPoint Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2016, closing a stake of 208 shares — an estimated $522K sold.

EverPoint Asset Management first reported a position in ACOR in Q2 2014 and held it in 5 quarters. The position peaked at $10.1M in Q2 2014. 175 funds tracked by Wall St. Rank hold ACOR as of Q4 2016.

EverPoint Asset Management reported no remaining Acorda Therapeutics position as of Q4 2016 after selling out during the quarter.
EverPoint Asset Management sold 208 Acorda Therapeutics shares in Q4 2016, an estimated $522K.
EverPoint Asset Management first reported a position in Acorda Therapeutics in Q2 2014 and held it in 5 quarters.
EverPoint Asset Management's Acorda Therapeutics position peaked at $10.1M in Q2 2014.
175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.